Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. Five analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $20.40 for the company and are anticipating that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also assigned BioXcel Therapeutics an industry rank of 101 out of 255 based on the ratings given to its competitors.
BTAI has been the subject of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $21.00 price target on shares of BioXcel Therapeutics in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of BioXcel Therapeutics in a report on Tuesday, June 12th.
Hedge funds have recently added to or reduced their stakes in the company. Barclays PLC purchased a new position in shares of BioXcel Therapeutics in the first quarter worth $6,331,000. Point72 Asset Management L.P. purchased a new position in shares of BioXcel Therapeutics in the first quarter worth $609,000. BlackRock Inc. purchased a new position in shares of BioXcel Therapeutics in the second quarter worth $137,000. California Public Employees Retirement System purchased a new position in shares of BioXcel Therapeutics in the first quarter worth $3,362,000. Finally, Millennium Management LLC purchased a new position in shares of BioXcel Therapeutics in the first quarter worth $316,000. 30.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of BioXcel Therapeutics traded down $0.75, reaching $9.25, during mid-day trading on Tuesday, according to MarketBeat Ratings. The stock had a trading volume of 28,760 shares, compared to its average volume of 32,226. BioXcel Therapeutics has a 12 month low of $6.76 and a 12 month high of $14.79.
BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.13. equities research analysts anticipate that BioXcel Therapeutics will post -1.37 earnings per share for the current fiscal year.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Featured Article: Average Daily Trade Volume Explained
Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.